Microarray analysis of nemorosone‐induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR)

Abstract

BACKGROUND AND PURPOSE Pancreatic cancer is one of the leading cancer‐related causes of death due to high chemo‐resistance and fast metastasation. Nemorosone, a polycyclic polyprenylated acylphloroglucinol, has recently been identified as a promising anticancer agent. Here, we examine its growth‐inhibitory effects on pancreatic cancer cells. Based on transcription profiling, a molecular mode of action is proposed. EXPERIMENTAL APPROACH Nemorosone cytotoxicity was assessed by the resazurin proliferation assay on pancreatic cancer cells and fibroblasts. Apoptosis was determined by Annexin V/propidium iodide staining as well as cytochrome c and caspase activation assays. Staining with the voltage‐dependent dye JC‐1 and fluorescence microscopy were used to detect effects on mitochondrial membrane potential. Total RNA was isolated from treated cell lines and subjected to microarray analysis, subsequent pathway identification and modelling. Gene expression data were validated by quantitative polymerase chain reaction and siRNA‐mediated gene knock‐down. KEY RESULTS Nemorosone significantly inhibited cancer cell growth, induced cytochrome c release and subsequent caspase‐dependent apoptosis, rapidly abolished mitochondrial membrane potential and elevated cytosolic calcium levels, while fibroblasts were largely unaffected. Expression profiling revealed 336 genes to be affected by nemorosone. A total of 75 genes were altered in all three cell lines, many of which were within the unfolded protein response (UPR) network. DNA damage inducible transcript 3 was identified as a key regulator in UPR‐mediated cell death. CONCLUSIONS AND IMPLICATIONS Nemorosone could be a lead compound for the development of novel anticancer drugs amplifying the already elevated UPR level in solid tumours, thus driving them into apoptosis. This study forms the basis for further investigations identifying nemorosone's direct molecular target(s).

Advances in the management of conjunctival melanoma

“…[3] The second agent, clusianone 502, also known as nemorosone, is an anti-tumor agent from the plant Clusia rosea studied in vitro on pancreatic carcinoma. [53]. Ranpirnase, a ribonuclease extracted from the frog Rana pipiens studied on malignant mesothelioma, also effectively inhibited growth of the conjunctival melanoma cells.…”

Genomic Analysis of Pterostilbene Predicts Its Antiproliferative Effects Against Pancreatic Cancer In Vitro and In Vivo

“…Our results show for the first time that pterostilbene significantly upregulates genomic expression of DDIT-3, growth differentiation factor 15, also known as macrophage inhibitory cytokine 1, and MnSOD, which are all associated with induction of pancreatic cancer cell death. 5-8,19,20 Pterostilbene also significantly upregulated heme oxygenase-1 (HO-1), an inducible stress-response protein. Enhanced HO-1 expression is thought to increase resistance to cell death; however, in pancreatic cancer cells, HO-1 is also upregulated in response to radiation, gemcitabine, and oxidative stress suggesting an anticancer effect.…”

In Vivo Activity and Pharmacokinetics of Nemorosone on Pancreatic Cancer Xenografts

“…More detailed analyses of its mechanism of action on pancreatic cancer cells showed rapid elevation of cyctosolic calcium levels and depolarization of the mitochondrial membrane followed by activation of apoptosis via a stress response pathway known as the unfolded protein response [12]. Interestingly, differentiated normal cells were found to be 10-times less sensitive to a treatment with nemorosone, thus opening a potential therapeutic window to explore also its anti-cancer activity in vivo .…”